vs
南玻集团（CSGS）与Pacira BioSciences, Inc.（PCRX）财务数据对比。点击上方公司名可切换其他公司
南玻集团的季度营收约是Pacira BioSciences, Inc.的1.8倍（$323.1M vs $177.4M），南玻集团净利率更高（2.2% vs 1.6%，领先0.5%），Pacira BioSciences, Inc.同比增速更快（5.0% vs 2.0%），过去两年南玻集团的营收复合增速更高（4.6% vs -0.2%）
中国南玻集团股份有限公司是中国规模最大的建筑玻璃生产商，业务涵盖浮法玻璃、建筑玻璃、显示玻璃、汽车玻璃、镀膜玻璃、镜子、彩滤玻璃、太阳能玻璃及节能玻璃等各类玻璃产品的研发、生产与销售，产品广泛应用于建筑、消费电子、新能源汽车、光伏等多个领域。
Pacira BioSciences是一家专科制药企业，专注于非阿片类疼痛管理药物的研发与商业化，核心产品线面向术后镇痛场景，服务以美国为主的医院、门诊手术中心等医疗服务机构，同时推进部分国际市场的拓展工作。
CSGS vs PCRX — 直观对比
营收规模更大
CSGS
是对方的1.8倍
$177.4M
营收增速更快
PCRX
高出3.0%
2.0%
净利率更高
CSGS
高出0.5%
1.6%
两年增速更快
CSGS
近两年复合增速
-0.2%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $323.1M | $177.4M |
| 净利润 | $7.0M | $2.9M |
| 毛利率 | 50.0% | — |
| 营业利润率 | 9.0% | 3.9% |
| 净利率 | 2.2% | 1.6% |
| 营收同比 | 2.0% | 5.0% |
| 净利润同比 | -79.7% | — |
| 每股收益（稀释后） | $0.24 | $0.07 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CSGSPCRX
| Q1 26 | — | $177.4M | ||
| Q4 25 | $323.1M | $196.9M | ||
| Q3 25 | $303.6M | $179.5M | ||
| Q2 25 | $297.1M | $181.1M | ||
| Q1 25 | $299.5M | $168.9M | ||
| Q4 24 | $316.7M | $187.3M | ||
| Q3 24 | $295.1M | $168.6M | ||
| Q2 24 | $290.3M | $178.0M |
净利润CSGSPCRX
| Q1 26 | — | $2.9M | ||
| Q4 25 | $7.0M | — | ||
| Q3 25 | $20.5M | $5.4M | ||
| Q2 25 | $12.3M | $-4.8M | ||
| Q1 25 | $16.1M | $4.8M | ||
| Q4 24 | $34.5M | — | ||
| Q3 24 | $19.1M | $-143.5M | ||
| Q2 24 | $13.8M | $18.9M |
毛利率CSGSPCRX
| Q1 26 | — | — | ||
| Q4 25 | 50.0% | 79.5% | ||
| Q3 25 | 48.1% | 80.9% | ||
| Q2 25 | 49.5% | 77.4% | ||
| Q1 25 | 48.4% | 79.7% | ||
| Q4 24 | 51.3% | 78.7% | ||
| Q3 24 | 49.4% | 76.9% | ||
| Q2 24 | 47.3% | 75.1% |
营业利润率CSGSPCRX
| Q1 26 | — | 3.9% | ||
| Q4 25 | 9.0% | 1.2% | ||
| Q3 25 | 10.0% | 3.5% | ||
| Q2 25 | 10.0% | 4.7% | ||
| Q1 25 | 9.8% | 1.2% | ||
| Q4 24 | 13.4% | 13.2% | ||
| Q3 24 | 10.8% | -82.8% | ||
| Q2 24 | 8.8% | 15.9% |
净利率CSGSPCRX
| Q1 26 | — | 1.6% | ||
| Q4 25 | 2.2% | — | ||
| Q3 25 | 6.7% | 3.0% | ||
| Q2 25 | 4.1% | -2.7% | ||
| Q1 25 | 5.4% | 2.8% | ||
| Q4 24 | 10.9% | — | ||
| Q3 24 | 6.5% | -85.1% | ||
| Q2 24 | 4.8% | 10.6% |
每股收益（稀释后）CSGSPCRX
| Q1 26 | — | $0.07 | ||
| Q4 25 | $0.24 | $0.05 | ||
| Q3 25 | $0.73 | $0.12 | ||
| Q2 25 | $0.44 | $-0.11 | ||
| Q1 25 | $0.57 | $0.10 | ||
| Q4 24 | $1.20 | $0.38 | ||
| Q3 24 | $0.67 | $-3.11 | ||
| Q2 24 | $0.48 | $0.39 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $180.0M | $144.3M |
| 总债务越低越好 | $539.5M | — |
| 股东权益账面价值 | $283.7M | $653.9M |
| 总资产 | $1.5B | $1.2B |
| 负债/权益比越低杠杆越低 | 1.90× | — |
8季度趋势，按日历期对齐
现金及短期投资CSGSPCRX
| Q1 26 | — | $144.3M | ||
| Q4 25 | $180.0M | $238.4M | ||
| Q3 25 | $158.4M | $246.3M | ||
| Q2 25 | $145.9M | $445.9M | ||
| Q1 25 | $136.0M | $493.6M | ||
| Q4 24 | $161.8M | $484.6M | ||
| Q3 24 | $118.4M | $453.8M | ||
| Q2 24 | $110.4M | $404.2M |
总债务CSGSPCRX
| Q1 26 | — | — | ||
| Q4 25 | $539.5M | $372.2M | ||
| Q3 25 | $538.6M | $376.7M | ||
| Q2 25 | $537.8M | $580.5M | ||
| Q1 25 | $537.6M | $583.4M | ||
| Q4 24 | $538.5M | $585.3M | ||
| Q3 24 | $539.5M | — | ||
| Q2 24 | $540.5M | — |
股东权益CSGSPCRX
| Q1 26 | — | $653.9M | ||
| Q4 25 | $283.7M | $693.1M | ||
| Q3 25 | $289.5M | $727.2M | ||
| Q2 25 | $290.7M | $757.8M | ||
| Q1 25 | $283.1M | $798.5M | ||
| Q4 24 | $282.6M | $778.3M | ||
| Q3 24 | $288.4M | $749.6M | ||
| Q2 24 | $273.3M | $879.3M |
总资产CSGSPCRX
| Q1 26 | — | $1.2B | ||
| Q4 25 | $1.5B | $1.3B | ||
| Q3 25 | $1.5B | $1.3B | ||
| Q2 25 | $1.4B | $1.5B | ||
| Q1 25 | $1.4B | $1.6B | ||
| Q4 24 | $1.5B | $1.6B | ||
| Q3 24 | $1.4B | $1.5B | ||
| Q2 24 | $1.4B | $1.6B |
负债/权益比CSGSPCRX
| Q1 26 | — | — | ||
| Q4 25 | 1.90× | 0.54× | ||
| Q3 25 | 1.86× | 0.52× | ||
| Q2 25 | 1.85× | 0.77× | ||
| Q1 25 | 1.90× | 0.73× | ||
| Q4 24 | 1.91× | 0.75× | ||
| Q3 24 | 1.87× | — | ||
| Q2 24 | 1.98× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $59.2M | — |
| 自由现金流经营现金流 - 资本支出 | $55.8M | — |
| 自由现金流率自由现金流/营收 | 17.3% | — |
| 资本支出强度资本支出/营收 | 1.1% | — |
| 现金转化率经营现金流/净利润 | 8.46× | — |
| 过去12个月自由现金流最近4个季度 | $141.4M | — |
8季度趋势，按日历期对齐
经营现金流CSGSPCRX
| Q1 26 | — | — | ||
| Q4 25 | $59.2M | $43.7M | ||
| Q3 25 | $47.9M | $60.8M | ||
| Q2 25 | $37.3M | $12.0M | ||
| Q1 25 | $11.5M | $35.5M | ||
| Q4 24 | $82.5M | $33.1M | ||
| Q3 24 | $39.5M | $53.9M | ||
| Q2 24 | $43.1M | $53.2M |
自由现金流CSGSPCRX
| Q1 26 | — | — | ||
| Q4 25 | $55.8M | $43.5M | ||
| Q3 25 | $43.9M | $57.0M | ||
| Q2 25 | $34.6M | $9.3M | ||
| Q1 25 | $7.1M | $26.9M | ||
| Q4 24 | $76.6M | $31.0M | ||
| Q3 24 | $32.0M | $49.8M | ||
| Q2 24 | $38.8M | $51.6M |
自由现金流率CSGSPCRX
| Q1 26 | — | — | ||
| Q4 25 | 17.3% | 22.1% | ||
| Q3 25 | 14.5% | 31.7% | ||
| Q2 25 | 11.6% | 5.1% | ||
| Q1 25 | 2.4% | 15.9% | ||
| Q4 24 | 24.2% | 16.6% | ||
| Q3 24 | 10.8% | 29.6% | ||
| Q2 24 | 13.4% | 29.0% |
资本支出强度CSGSPCRX
| Q1 26 | — | — | ||
| Q4 25 | 1.1% | 0.1% | ||
| Q3 25 | 1.3% | 2.2% | ||
| Q2 25 | 0.9% | 1.5% | ||
| Q1 25 | 1.5% | 5.1% | ||
| Q4 24 | 1.9% | 1.1% | ||
| Q3 24 | 2.5% | 2.4% | ||
| Q2 24 | 1.5% | 0.9% |
现金转化率CSGSPCRX
| Q1 26 | — | — | ||
| Q4 25 | 8.46× | — | ||
| Q3 25 | 2.34× | 11.20× | ||
| Q2 25 | 3.04× | — | ||
| Q1 25 | 0.71× | 7.37× | ||
| Q4 24 | 2.39× | — | ||
| Q3 24 | 2.07× | — | ||
| Q2 24 | 3.12× | 2.82× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CSGS
| Software As A Service And Related Solutions | $287.2M | 89% |
| License And Service | $22.6M | 7% |
| Maintenance | $13.3M | 4% |
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
